Monogenic Kidney Stone - Genetic Testing

Description

This study will attempt to identify the specific gene (coded in the DNA) and changes (mutations) within that gene that are the cause of monogenic kidney stone disease. This study will help researchers determine the characteristics of the stone disease associated with specific genes and mutations. This information may help develop more effective treatments for monogenic kidney stone diseases.

Conditions

Rare Kidney Stone Diseases

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will attempt to identify the specific gene (coded in the DNA) and changes (mutations) within that gene that are the cause of monogenic kidney stone disease. This study will help researchers determine the characteristics of the stone disease associated with specific genes and mutations. This information may help develop more effective treatments for monogenic kidney stone diseases.

Characterization of Monogenic Kidney Stone Diseases

Monogenic Kidney Stone - Genetic Testing

Condition
Rare Kidney Stone Diseases
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients \<18yrs with a history of kidney stones, and/or nephrocalcinosis, OR
  • 2. Patients \>18yrs with a history of kidney stones, and/or nephrocalcinosis and at least one of the following:
  • 1. Family history of stones or nephrocalcinosis or unexplained kidney failure
  • 2. Growth retardation
  • 3. Metabolic bone disease
  • 4. Unusual stone composition or pathologic or urinary crystals
  • 5. Proteinuria
  • 6. Reduced glomerular filtration rate (GFR)
  • 7. Hypomagnesemia or hypophosphatemia or hypercalcemia
  • 8. Increased oxalate
  • 9. Renal cysts, OR
  • 3. Patients with a high clinical suspicion for a monogenic kidney stone disease or a disorder of calcium metabolism OR
  • 4. Patients previously enrolled in the Rare Kidney Stone Consortium 6406 protocol (identified as legacy samples), "Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria." These patients have already consented for their samples to be used in genetic research and that consent will serve to enroll them in this study, OR
  • 5. Patients previously enrolled in the Rare Kidney Stone Consortium 6403 protocol (identified as legacy samples), "Screening for Dent Disease Mutations in Patients with Proteinuria or Hypercalciuria and Calcium Urolithiasis." These patients have already consented for their samples to be used in genetic research and that consent will serve to enroll them in this study, OR
  • 6. Family member of a patient that meets at least one of the above criteria
  • 1. Stone formers who do not meet the inclusion criteria for clinical suspicion of one of the monogenic kidney stone diseases
  • 2. Unwilling or unable to provide consent/assent

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

David Sas, DO, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2028-02